# Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/healthcare-resource-utilization-in-patients-with-metastatic-melanoma-receiving/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Sameer R. Ghate,Raluca Ionescu‐Ittu,Rebecca Burne,Briana Ndife,François Laliberté,Antônio Nakasato,Mei Sheng Duh |
| Citations | 8 |
| DOI | 10.1080/03007995.2018.1501351 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://www.tandfonline.com/doi/pdf/10.1080/03007995.2018.1501351?download=true |
| OpenAlex ID | https://openalex.org/W2883913077 |
| PMID | 30009647 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Briana Ndife](https://scholariq.org/researchers/briana-ndife/)

## Paper journal

- [Current Medical Research and Opinion](https://scholariq.org/journals/current-medical-research-and-opinion/)

## Paper primary topic

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

## Paper topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.